510 related articles for article (PubMed ID: 28104208)
1. First-in-Human Evaluation of a Novel Polymer-Free Drug-Filled Stent: Angiographic, IVUS, OCT, and Clinical Outcomes From the RevElution Study.
Worthley SG; Abizaid A; Kirtane AJ; Simon DI; Windecker S; Brar S; Meredith IT; Shetty S; Sinhal A; Almonacid AP; Chamié D; Maehara A; Stone GW;
JACC Cardiovasc Interv; 2017 Jan; 10(2):147-156. PubMed ID: 28104208
[TBL] [Abstract][Full Text] [Related]
2. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
[TBL] [Abstract][Full Text] [Related]
3. Polymer-free Biolimus A9-coated stents in the treatment of de novo coronary lesions with short DAPT: 9-month angiographic and clinical follow-up of the prospective, multicenter BioFreedom USA clinical trial.
Waksman R; Piegari GN; Kabour A; Cannon L; Wang J; Adams G; Solankhi N; Smeglin A; Kereiakes DJ; Leiboff R; Spad MA; Torguson R; Chandra N; Bastian R; DeGroot J; Kayo MW; Stoll HP; Garcia-Garcia HM
Cardiovasc Revasc Med; 2017; 18(7):475-481. PubMed ID: 28923692
[TBL] [Abstract][Full Text] [Related]
4. The OCT-ORION Study: A Randomized Optical Coherence Tomography Study Comparing Resolute Integrity to Biomatrix Drug-Eluting Stent on the Degree of Early Stent Healing and Late Lumen Loss.
Lee SWL; Tam FCC; Lam SCC; Kong SL; Shea CP; Chan KKW; Wong MKL; Chan MPH; Wong AYT; Yung ASY; Lam YM; Zhang LW; Wu KKY; Mintz GS; Maehara A
Circ Cardiovasc Interv; 2018 Apr; 11(4):e006034. PubMed ID: 29654119
[TBL] [Abstract][Full Text] [Related]
5. First-in-man study evaluating the safety and efficacy of a second generation biodegradable polymer sirolimus-eluting stent in the treatment of patients with de novo coronary lesions: clinical, Angiographic, and OCT outcomes of CREDIT-1.
Wang G; Sun Z; Jin Q; Xu K; Li Y; Wang X; Ma Y; Liu H; Zhao X; Wang B; Deng J; Guan S; Ge M; Wang X; Xu B; Han Y
Catheter Cardiovasc Interv; 2015 Mar; 85 Suppl 1():744-51. PubMed ID: 25630447
[TBL] [Abstract][Full Text] [Related]
6. Randomized Multicenter Trial Investigating Angiographic Outcomes of Hybrid Sirolimus-Eluting Stents With Biodegradable Polymer Compared With Everolimus-Eluting Stents With Durable Polymer in Chronic Total Occlusions: The PRISON IV Trial.
Teeuwen K; van der Schaaf RJ; Adriaenssens T; Koolen JJ; Smits PC; Henriques JP; Vermeersch PH; Tjon Joe Gin RM; Schölzel BE; Kelder JC; Tijssen JG; Agostoni P; Suttorp MJ
JACC Cardiovasc Interv; 2017 Jan; 10(2):133-143. PubMed ID: 28104206
[TBL] [Abstract][Full Text] [Related]
7. Nine-month angiographic and 2-year clinical follow-up of the NOYA biodegradable polymer sirolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the NOYA I trial.
Xu B; Dou K; Yang Y; Lv S; Wang L; Wang H; Li Z; Wang L; Chen Y; Huo Y; Li W; Kirtane AJ; Gao R
EuroIntervention; 2012 Nov; 8(7):796-802. PubMed ID: 23171800
[TBL] [Abstract][Full Text] [Related]
8. Three- and 6-month optical coherence tomographic surveillance following percutaneous coronary intervention with the Angiolite® drug-eluting stent: The ANCHOR study.
Puri R; Otaegui I; Sabaté M; Serra-Peñaranda A; Puigfel M; Perez de Prado A; Nombela-Franco L; de la Torre Hernandez JM; Ortas Nadal R; Iniguez-Romo A; Jiménez G; Fernandez-Vazquez F; Cuellas-Ramon C; Gonzalo N; Alfonso Jiménez Diaz V; Duocastella L; Molina M; Amoros M; Perez I; Barria Perez A; Pelletier Beaumont E; Nicholls SJ; Garcia Del Blanco B; Rodés-Cabau J
Catheter Cardiovasc Interv; 2018 Feb; 91(3):435-443. PubMed ID: 28707379
[TBL] [Abstract][Full Text] [Related]
9. Metallic Limus-Eluting Stents Abluminally Coated with Biodegradable Polymers: Angiographic and Clinical Comparison of a Novel Ultra-Thin Sirolimus Stent Versus Biolimus Stent in the DESTINY Randomized Trial.
Lemos PA; Abizaid AA; Meireles GC; Sarmento-Leite R; Prudente M; Cantarelli M; Dourado AD; Mariani J; Perin MA; Costantini C; Costa RA; Costa JR; Chamie D; Campos CA; Ribeiro E
Cardiovasc Ther; 2015 Dec; 33(6):367-71. PubMed ID: 26352896
[TBL] [Abstract][Full Text] [Related]
10. A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial.
Gao RL; Xu B; Lansky AJ; Yang YJ; Ma CS; Han YL; Chen SL; Li H; Zhang RY; Fu GS; Yuan ZY; Jiang H; Huo Y; Li W; Zhang YJ; Leon MB;
EuroIntervention; 2013 May; 9(1):75-83. PubMed ID: 23685298
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of the next generation Resolute Onyx zotarolimus-eluting stent: Primary outcome of the RESOLUTE ONYX core trial.
Price MJ; Shlofmitz RA; Spriggs DJ; Haldis TA; Myers P; Popma Almonacid A; Maehara A; Dauler M; Peng Y; Mehran R
Catheter Cardiovasc Interv; 2018 Aug; 92(2):253-259. PubMed ID: 28940882
[TBL] [Abstract][Full Text] [Related]
12. First Report of the Resolute Onyx 2.0-mm Zotarolimus-Eluting Stent for the Treatment of Coronary Lesions With Very Small Reference Vessel Diameter.
Price MJ; Saito S; Shlofmitz RA; Spriggs DJ; Attubato M; McLaurin B; Popma Almonacid A; Brar S; Liu M; Moe E; Mehran R
JACC Cardiovasc Interv; 2017 Jul; 10(14):1381-1388. PubMed ID: 28728650
[TBL] [Abstract][Full Text] [Related]
13. Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent.
Meredith IT; Verheye S; Weissman NJ; Barragan P; Scott D; Valdés Chávarri M; West NE; Kelbæk H; Whitbourn R; Walters DL; Kubica J; Thuesen L; Masotti M; Banning A; Sjögren I; Stables RH; Allocco DJ; Dawkins KD
EuroIntervention; 2013 Jul; 9(3):308-15. PubMed ID: 23872647
[TBL] [Abstract][Full Text] [Related]
14. Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China: the RESOLUTE China randomized controlled trial.
Xu B; Yang Y; Yuan Z; Du Z; Wong SC; Généreux P; Lu S;
JACC Cardiovasc Interv; 2013 Jul; 6(7):664-70. PubMed ID: 23523240
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Early Healing Profile and Neointimal Transformation Over 24 Months Using Longitudinal Sequential Optical Coherence Tomography Assessments and 3-Year Clinical Results of the New Dual-Therapy Endothelial Progenitor Cell Capturing Sirolimus-Eluting Combo Stent: The EGO-Combo Study.
Lee SW; Lam SC; Tam FC; Chan KK; Shea CP; Kong SL; Wong AY; Yung A; Zhang LW; Tse HF; Wu KK; Chan R; Haude M; Mehran R; Mintz GS; Maehara A
Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27418609
[TBL] [Abstract][Full Text] [Related]
16. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial.
Onuma Y; Dudek D; Thuesen L; Webster M; Nieman K; Garcia-Garcia HM; Ormiston JA; Serruys PW
JACC Cardiovasc Interv; 2013 Oct; 6(10):999-1009. PubMed ID: 24156961
[TBL] [Abstract][Full Text] [Related]
17. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
Kandzari DE; Mauri L; Popma JJ; Turco MA; Gurbel PA; Fitzgerald PJ; Leon MB
JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327
[TBL] [Abstract][Full Text] [Related]
18. Angiographic and clinical comparison of novel Orsiro Hybrid sirolimus-eluting stents and Resolute Integrity zotarolimus-eluting stents in all-comers with coronary artery disease (ORIENT trial): study protocol for a randomized controlled trial.
Lee JM; Park SD; Lim SY; Doh JH; Cho JM; Kim KS; Bae JW; Chung WY; Youn TJ
Trials; 2013 Nov; 14():398. PubMed ID: 24257456
[TBL] [Abstract][Full Text] [Related]
19. The REMEDEE trial: a randomized comparison of a combination sirolimus-eluting endothelial progenitor cell capture stent with a paclitaxel-eluting stent.
Haude M; Lee SW; Worthley SG; Silber S; Verheye S; Erbs S; Rosli MA; Botelho R; Meredith I; Sim KH; Stella PR; Tan HC; Whitbourn R; Thambar S; Abizaid A; Koh TH; Den Heijer P; Parise H; Cristea E; Maehara A; Mehran R
JACC Cardiovasc Interv; 2013 Apr; 6(4):334-43. PubMed ID: 23523459
[TBL] [Abstract][Full Text] [Related]
20. Comparison of long-term in-stent vascular response between abluminal groove-filled biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent: 3-year OCT follow-up from the TARGET I trial.
Xu B; Zhang YJ; Sun ZW; Qiao SB; Chen SL; Zhang RY; Pan DR; Pang S; Zhang Q; Xu L; Yang YJ; Leon MB; Gao RL
Int J Cardiovasc Imaging; 2015 Dec; 31(8):1489-96. PubMed ID: 26208685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
